How old is patient?
Ceftriaxone Na indications
Treatment of the following infections when caused by susceptible aerobic organisms.
Lower respiratory tract infections caused by Streptococcus pneumoniae, Streptococcus species (excluding enterococci), methicillin-sensitive Staphylococcus aureus, Haemophilus influenzae, H. parainfluenzae, Klebsiella species (including K. pneumoniae), Escherichia coli, Enterobacter aerogenes, Proteus mirabilis and Serratia marcescens.
Skin and skin structure infections caused by methicillin-sensitive Staphylococcus aureus, methicillin-sensitive Staphylococcus epidermidis, Streptococcus Group B, Streptococcus Group G, Streptococcus pyogenes, Streptococcus viridans, Streptococcus species (excluding enterococci), Peptostreptococcus species, Escherichia coli, Enterobacter cloacae, Klebsiella species (including K. pneumoniae, K. oxytoca), Proteus mirabilis, Morganella morganii and Serratia marcescens.
Urinary tract infections (complicated and uncomplicated) caused by E. coli, Proteus mirabilis, Proteus vulgaris, M. morganii and Klebsiella species (including K. pneumoniae).
Uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae, including penicillinase- and nonpenicillinase-producing strains.
Bacterial septicemia caused by Streptococcus pneumoniae, E. coli and H. influenzae.
Bone infections caused by methicillin-sensitive S. aureus, methicillin-sensitive S. epidermidis, Stretococcus Group B, Streptococcus pneumoniae, Streptococcus species (excluding enterococci), E. coli, Enterobacter species, P. mirabilis and K. pneumoniae.
Joint infections caused by methicillin-sensitive S. aureus, Streptococcus pneumoniae, Streptococcus species (excluding enterococci), E. coli, P. mirabilis, K. pneumoniae and Enterobacter species.
Meningitis: The initial treatment, as a single agent, of meningitis in children and immunocompetent adults when presumed or proven to be caused by Haemophilus influenzae type b, Neisseria meningitidis, Streptococcus pneumoniae or Enterobacteriaceae pending culture and sensitivity results.
Surgical Prophylaxis: The preoperative administration of a single 1 g dose of ceftriaxone may reduce the incidence of postoperative infections in patients undergoing vaginal or abdominal hysterectomy or cholecystectomy in high risk patients, surgical procedures which are classified as contaminated or potentially contaminated and patients undergoing coronary artery bypass surgery. Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo controlled trials have been conducted.
Susceptibility Testing: Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing.
Ceftriaxone Na description
Each vial contains ceftriaxone sodium 1.19 g equivalent to ceftriaxone 1 g.
Ceftriaxone Na is a sterile, semisynthetic, broad spectrum cephalosphorin antibiotic for IV or IM administration. It contains approximately 83 mg (3.6mEq) of sodium per g of ceftriaxone activity.
Ceftriaxone sodium is disodium (6R,7R)-[[(2Z)-2-aminothiazol-4-yl)methoxyimino)acetyl]amino]-3-[[(2-methyl-6-oxido-5-oxo-2,5-dihydro-1,2,4-triazin-3-yl)sulphanyl]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate 3,5 hydrate.
The chemical formula of ceftriaxone sodium is C18H16N8Na2O7S3·3½H2O. It has a calculated molecular weight of 661.59 (CAS Registry Number: 104376-79-6).
Ceftriaxone sodium is a white or yellowish crystalline powder which is very soluble in water, sparingly soluble in methanol and very slightly soluble in ethanol. The pH of a 5% aqueous solution is approximately 6-8. Ceftriaxone sodium solutions may be light yellow to amber-colored in color.
Active ingredient matches for Ceftriaxone Na:
ReviewsThe results of a survey conducted on nDrugs.com for Ceftriaxone Na are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Ceftriaxone Na. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Consumer reported usefulNo survey data has been collected yet
Consumer reported price estimatesNo survey data has been collected yet
Consumer reported time for resultsNo survey data has been collected yet
Consumer reported ageNo survey data has been collected yet